Tigermed, a China Clinical Stage CRO, Plans ChiNext IPO - FLASH: Price set
10:35 EDT 5 Aug 2012 | ChinaBio Today
Tigermed Consulting, the clinical stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange. The company will offer 13.4 million A shares, which will constitute 25% of the company expanded share base. The company plans to pric..
Original Article: Tigermed, a China Clinical Stage CRO, Plans ChiNext IPO - FLASH: Price set
More From BioPortfolio on "Tigermed, a China Clinical Stage CRO, Plans ChiNext IPO - FLASH: Price set"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
